Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Day: September 14, 2022
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions...
Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
Data include the persistence of immune responses and protection against variants of concern, especially Delta and OmicronOcugen has North American...
Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million...
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022
Tessa developing allogeneic “off-the-shelf” CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomasSINGAPORE, Sept. 14, 2022...
JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial
Landmark ALIGN-AR Pivotal IDE Study Intended to Evaluate Use of the Trilogy™ Heart Valve System in Treatment of High Surgical...
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Samsung Bioepis Obtains Two ISO Certifications for Environmental Management System and Energy Management System
Obtains ISO 14001 (Environmental Management System) and ISO 50001 (Energy Management System)Recognized for continuous practices and commitment to enhancing sustainability...
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models...
EssilorLuxottica and the Armani Group announce 15-year licensing renewal
EssilorLuxottica and the Armani Group announce 15-year licensing renewal The renewal, four months ahead of the deadline, of the current...